Corticosteroids are still first-line therapies for bullous pemphigoid, with biologics finding use in difficult-to-treat disease.

Bullous pemphigoid is an autoantibody-mediated subepidermal blistering disorder which develops predominately in patients of advanced age. Corticosteroids remain as the first line of treatment for this disorder, although for difficult-to-treat cases (relapsing, corticosteroid-dependent, corticosteroid-resistant) or where corticosteroids are contraindicated, conventional immunotherapy or newer biologic agents can be used (as adjuvant or monotherapy). While new biologics are under evaluation for bullous pemphigoid, stronger evidence is still required for the majority of these new treatments. [ABSTRACT FROM AUTHOR]